EICHOR
● Terminated
Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus
Condition: Discoid Lupus Erythematosus · Sponsor: Amgen
About this study
A Phase 2, double-blind, randomized, placebo-controlled parallel-group study to evaluate the efficacy and safety of daxdilimab in participants with moderate-to-severe active primary Discoid Lupus Erythematosus (DLE) refractory to standard of care.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (68)
| Arkansas Research Trials | North Little Rock, Arkansas, United States | — |
| Wallace Medical Group | Beverly Hills, California, United States | — |
| The Center for Dermatology Clinical Research | Fremont, California, United States | — |
| Clinical Science Institute | Santa Monica, California, United States | — |
| Miami Dermatology & Laser Research | Miami, Florida, United States | — |
| Dawes Fretzin Clinical Research Group, LLC | Indianapolis, Indiana, United States | — |
| Detroit Clinical Research Center, PC | Farmington Hills, Michigan, United States | — |
| Michigan Dermatology Institute | Waterford, Michigan, United States | — |
| Minnesota Clinical Study Center | New Brighton, Minnesota, United States | — |
| MediSearch Clinical Trials | Saint Joseph, Missouri, United States | — |
| Forest Hills Dermatology | Forest Hills, New York, United States | — |
| Ohio State University | Columbus, Ohio, United States | — |
+ 56 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05591222